Triple drug combo effective for lowering blood pressure, LDL-C levels
Treatment with triple combination of amlodipine, losartan and rosuvastatin appears to be an effective therapeutic strategy for lowering blood pressure (BP) and low-density lipoprotein (LDL)-C levels in patients with comorbid hypertension and dyslipidaemia, according to a study.
A total of 146 patients with a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250 mg/dL were randomized to one the following treatment regimens: losartan potassium 100 mg plus rosuvastatin 20 mg (L/R group), amlodipine camsylate 5 mg plus losartan potassium 100 mg (A/L group), and amlodipine 5 mg plus losartan potassium 100 mg plus rosuvastatin 20 mg (A/L/R group).
The 8-week treatment was initiated after a 4-week run-in period during which patients underwent therapeutic lifestyle changes and took losartan potassium 100 mg once daily, with a goal to achieve blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria.
Of the patients, 138 completed treatment and 143 were included in the full analysis. After 8 weeks, A/L/R yielded a significantly greater mean percent change in LDL-C compared with L/R (–48.40 vs –6.70 percent; p<0.0001). Likewise, the mean change in SiDBP was significantly greater with A/L/R vs A/L (–9.75 vs –1.73 mm Hg; p<0.0001).
Researchers noted that LDL-C and SiDBP reductions in the A/L/R group were comparable to reductions in the L/R and A/L groups, respectively.
With respect to safety, 10 adverse events occurred in seven patients, including three in the A/L/R group, two in the A/L group and another two in the L/R group. Tachycardia and face oedema were considered adverse drug reactions, but these events were mild and resolved without specific treatment. No clinically significant tolerability issues were reported during the treatment period.
Findings of the present study “will form the foundation of the future development of a single-pill triple combination,” researchers said.